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Abstract 
Objectives. The long-term effects of amino acid–based formula (AAF) in the treatment of  cow’s 
milk allergy (CMA) is largely unexplored. This study comparatively evaluates body growth and 
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protein metabolism in CMA children treated with AAF or with extensively hydrolysed whey 
formula (eHWF), and healthy controls (HCs).  
Methods. A 12-month multicentre randomised control trial (RCT) was conducted in outpatients 
with CMA (aged 5–12 m) randomised in two groups, treated with AAF (Group 1) and eHWF 
(Group 2), and compared with HCs (Group 3) fed with follow-on (if age <12 m) or growing-up 
formula (if age >12 m). At enrolment (T0), after 3 (T3), 6 (T6) and 12 months  (T12) a clinical 
evaluation was performed. At T0 and T3, were dosed in CMA subjects serum levels of albumin, 
urea, total protein, retinol binding protein, and insulin-like growth factor 1 (IGF-1).  
Results. 21 subjects in Group 1 (61.9% male, aged 6.5 ±1.5 m), 19 in Group 2 (57.9% male, aged 7 
±1.7 m) and 25 subjects in Group 3 (48% male, aged 5.5±0.5 m) completed the study. At T0, the 
weight z-score was similar in Group 1 (−0.74) and 2 (−0.76), with differences compared to Group 3 
(−0.17, p < 0.05). At T12, the weight z-score value was similar between the three groups without 
significant differences. There were no significant changes in protein metabolism in children in 
Groups 1 and 2. 
Conclusions. Long-term treatment with AAF is safe and allows adequate body growth in CMA 
children without alterations in protein metabolism. 
 
Keywords: Body length, body weight, extensively hydrolysed whey formula, retinol binding 
protein, serum albumin 
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What Is Known: 
 The epidemiological pattern of cow’s milk allergy has changed during the last decades with 
increased risk of persistence and severity of clinical manifestations. 
 Cow’s milk exclusion diet is the only available treatment, and may lead to nutritional 
deficiencies and poor growth.  
 Amino acid–based formula is currently used in patients that are non-responsive to or 
intolerant of other treatments, but data on long-term use are limited by short-term 
observation periods.  
 
What Is New:  
 The long-term use of amino acid–based formula is able to stimulate a growth pattern similar 
to extensively hydrolysed whey formula in children with cow’s milk allergy.  
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Introduction 
Cow's milk allergy (CMA) is one of the most common food allergies in childhood. The 
epidemiological pattern of the disease has changed during the last decades with an increased 
severity of clinical manifestations and risk of persistence (1,2). The actual prevalence in children 
under 3 years of age is up to 3% in industrialised countries (3,4). CMA is the leading cause of food-
induced anaphylaxis requiring hospitalisation in the Italian paediatric population (5,6). Recent data 
shows that only about a half of these patients  acquire oral tolerance 2 years after CMA diagnosis 
(2,7).  
A diet that excludes cow’s milk is the only available treatment (8,9). There are two main goals of 
nutritional intervention for patients with CMA: preventing allergic reactions through allergen 
avoidance and ensuring optimal nutrition and body growth on the restricted diet. Cow’s milk 
exclusion diets without appropriate substitution may lead to nutritional deficiencies and poor 
growth (10). A summary report from an international consensus panel of allergy specialists 
recommends substituting a formula "of adequate nutritional value" or breast milk until 2 years of 
age. Suitable formulas include extensively hydrolysed whey formula (eHWF) and amino acid–
based formula (AAF), which are considered to be hypoallergenic. The total protein content and 
composition of these two formulas are similar, but the form in which the amino acids are delivered 
to the infant is different, with the latter containing only free amino acids. These differences may 
have implications in protein metabolism (11). 
Amino acid–based formula is currently used in all cases that are non-responsive to or intolerant of 
treatment with eHWF and in all cases characterised by severe allergic reactions and multiple food 
allergies because this formula is by definition nonallergenic (12). AAF is able to ensure a rapid 
recovery from clinical symptoms (12–14), but data on long-term use are limited by short-term 
observation periods (up to 6–9 months) and by a lack of healthy controls evaluation (8,14–16). 
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Considering the changing scenario of CMA, it is important to better define the long-term effect of 
AAF strategy on body growth and protein metabolism.  
In this study, we aimed to comparatively evaluate the effects on body growth and protein 
metabolism of AAF and eHWF in CMA children with a parallel age-matched healthy group on an 
unrestricted diet. The primary study outcome was the evaluation of possible differences in body 
weight z-score after 12 months of treatment among the groups. Secondary study outcomes include 
possible differences in length and head circumference z-scores after 12 months of treatment, and 
possible differences in protein metabolism biomarkers. 
 
Methods 
 
Study design  
This multicentre randomised control trial was conducted in consecutive outpatient infants (aged 5–
12 months) referred to three Italian tertiary centres for Pediatric Allergy and Nutrition (located in 
Naples, Rome, and Milan) for strongly suspected CMA, but still receiving cow’s milk proteins.  
The study design was discussed. According to a centralised randomisation list, subjects were 
allocated to one of the two groups of dietary interventions: Group 1, patients receiving AAF 
(Neocate
®
, Nutricia, Milan, Italy for children up to the age of 12 months, switched to Neocate
®
 
Advance, Nutricia, Milan Italy after the completion of the 12
th
 month of age); and Group 2, patients 
receiving an eHWF (Hypolac DMF srl, Limbiate, Italy). When full and stable remission of CMA 
symptoms was achieved, a double-blind placebo-controlled food challenge (DBPCFC) was 
performed as previously described (4,17,18). Briefly, every 20 minutes, successive doses (0.1, 0.3, 
1, 3, 10, 30, and 100 mL) of fresh pasteurised cow’s milk (CM) containing 3.5% fat or an amino 
acid–based formula were administered. Full emergency equipment and medications (epinephrine, 
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antihistamines, and steroids) were available. The results were assessed simultaneously by three 
experienced paediatric allergists. Study subjects were scored for 9 items divided into 4 main 
categories: i. General (lowered blood pressure plus tachycardia); ii. Skin (rash, 
urticaria/angioedema); iii. Gastrointestinal (nausea/repeated vomiting, crampy-like abdominal pain, 
diarrhoea); and iv. Respiratory (sneezing/itching, nasal congestion/rhinorrhea, stridor deriving from 
upper airway obstruction or wheezing) on a 0- to 3-point scale (0, none; 1, light; 2, moderate; and 3, 
severe). If at least 2 of the 3 physicians independently scored any item at level 3, or 2 (or more) 
items at level 2, the test result was considered positive. Clinical symptoms occurring within 2 h of 
administering the highest dose were defined as ―immediate reactions.‖ The infants were observed 
for 2 h after the final dose and then discharged. In the case of a positive DBPCFC at any testing 
dose, the patient remained under observation until symptom resolution. If the patient did not show 
any symptoms within the first 24 hours, parents were advised to give one single feed of 100 ml of 
the tested formula (verum or placebo) every day at home for 7 days. If any symptoms occurred 
during this period, the patients returned to the outpatient clinic on the same day. After 7 days of 
verum or placebo administration, the patients were examined and the parents interviewed at the 
centre. To rule out false-negative challenge results, parents were asked to contact the centre if any 
symptoms occurred in the following 7 days after the DBPCFC procedures. The challenge was 
considered negative if the patient tolerated the entire challenge, including the observation period.  
Only infants with DBPCFC-based CMA diagnoses continued the trial. During the same period, a 
third parallel group of age-matched healthy children on an unrestricted diet was consecutively 
evaluated at the centres while undergoing minor surgical procedures and enrolled as controls 
(Group 3). These children assumed a follow-on formula up to the age of 12 months and were 
switched to growing-up formula after the completion of the 12
th
 month of age.  
The nutrient composition of the formulas consumed by study subjects is reported in Table 1. 
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We excluded patients with a history of prematurity; CMA-induced anaphylaxis; other concomitant 
food allergies; eosinophilic disorders of the gastrointestinal tract; chronic systemic diseases; chronic 
infections; immunodeficiencies; inflammatory bowel diseases; primary gastroesophageal reflux 
disease; celiac disease; cystic fibrosis; metabolic diseases; malignancies; chronic pulmonary, 
respiratory, cardiac, and renal diseases; malformations; chronic neuropsychiatric diseases; renal 
failure; or moderate to severe malnutrition at enrolment (body weight for age z-score: <−2 SD). 
Written informed consent was obtained from the parents/tutors of each study subject. The study was 
approved by the ethics committee of each institution and was registered in the Clinical Trials 
Protocol Registration System (ID number NCT02379598).  
All subjects were evaluated not by the investigators, but by a multidisciplinary team (unaware of the 
study aims and in charge at the three centres), comprised of a paediatrician, a nurse, and a dietitian 
at enrolment (T0) and at 3- (T1), 6- (T2), and 12-month (T3) control visits. The medical record of 
each child was recorded on a clinical chart. 
At each visit, the following variables were determined:  
I. Weight, length or height, and head circumference were measured using standard 
procedures (11).  
II. Anthropometric indices (z-score for weight, z-score for length/height, z-score for head 
circumference) were determined using the Euro-Growth References (19,20).  
III. Seven-day food record was analysed using ad hoc software based on the Italian food 
composition tables (Winfood Pro 3.7, released 2012, Medimatica Srl, Teramo, Italy) (21). 
IV.  Food allergy–related signs and symptoms were recorded. 
At each visit, the dietitian explained to parents how to record the amount and type of foods and 
drinks consumed by the child over a period of 7 consecutive days, including 5 weekdays and 2 
weekend days. The chart also contained instructions about how to record the food consumed and 
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how to measure food using graduated bowls, cups, dishes, and spoons. Seven days after enrolment 
and at each subsequent visit, the dietitian examined the dietary history and reviewed the food 
records. Starting from the enrolment visit, study subjects underwent a personalised dietary 
counselling session with the dietitian, as previously described (22). Briefly, dietary counselling was 
based on the evaluation of (i) body weight, length/height, weight-to-height ratio, and head 
circumference; (ii) protein and energy requirements. At each visit, the diet of study subjects was 
carefully assessed with the aim to give 400–600 ml/day of formula together with correct total 
energy and nutrient intake. The key words and phrases used during dietary counselling were 
emphasised to encourage discussion about food-related topics at home.  
At T0 and T3, venous blood sampling (2 ml) was performed after an overnight fast in subjects with 
CMA to determine serum biomarkers of protein metabolism (urea, total proteins, albumin, retinol 
binding protein, insulin-like growth factor 1 (IGF-1)). Samples were labelled with an anonymous 
identification code and stored at −20°C until analysis.  
All samples were analysed during the same session using the same lot of reagents by personnel 
unaware of the study aims and group assignment. In particular, retinol binding protein was 
measured using Dimension Vista, an automated immunoturbidimetric platform (Siemens Healthcare 
Diagnostics Products, Milan, Italy).  
Urea, total proteins, and albumin were measured using Cobas 8000 c702, a fully automated UV 
kinetic and colourimetric platform (Roche/ Hitachi Manufacture, Holliston, Massachusetts).  
IGF-1 was measured using Liason XL (DiaSorin Manufacture, Saluggia, Italy), a fully automated 
chemiluminescence analyser.  
Sample Size 
To detect a possible difference between Groups 1 and 2, up to 0.2 in the z-score for body weight at 
12 months, 19 subjects per group were requested (type I error of 5%, power 81%). Considering that 
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patients were enrolled before diagnostic challenge for CMA, and  possible dropouts, this number 
was increased to 25 per group.  
 
Statistics 
Intention-to-treat (ITT) and per-protocol (PP) analyses were conducted.  For continuous variables, 
groups were compared using equality of means testing. The χ2 test and Fisher’s exact test were used 
for categorical variables. When necessary, comparisons were performed with nonparametric tests 
(Wilcoxon–Mann–Whitney U test). Results were reported as means and 95% confidence interval 
(CI) and as median and interquartile range (IQR) due to nonnormal distribution (established by the 
Kolmogorov test). The level of significance for all statistical tests was 2-sided, p < 0.05. All data 
were collected in a dedicated database and analysed by a statistician who was unaware of patients’ 
group assignment, with IBM SPSS Statistics version 19.0 for Windows (SPSS Inc, Chicago, IL). 
 
Results  
 
The flow of the study population is reported in Figure 1 (see also Supplemental Digital Content, 
http://links.lww.com/MPG/A745). 56 consecutive subjects were evaluated for the study; 6 children 
were excluded because the presence of exclusion criteria. Fifty were randomized into 2 study 
groups and 10 were excluded after negative DBPCFC for cow’s milk.  
Main baseline features of the study groups are described in Table 2. Table 3 reports main baseline 
features of subjects with positive diagnostic DBPCFC who continued the treatment with the dietary 
products: 21 subjects in Group 1 and 19 in Group 2. CMA signs and symptoms recovered within 
the first 2 weeks of treatment in all patients without differences between subjects enrolled in Groups 
1 and 2. No patient had other food allergies during the study period.  
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Per-protocol analysis revealed that at T0, body weight z-score values were not significantly 
different between the two intervention groups (Groups 1 and 2), but were significantly lower if 
compared to Group 3 (Figure 2, Panel a). Use of both hypoallergenic formulas resulted in similar 
weight gain for CMA subjects during the 12-month study period. At T3, a difference in body 
weight z-score was observed in Groups 1 and 2 compared to healthy children (Group 3). But at T6, 
no significant differences in body weight z-score were observed comparing CMA subjects and 
healthy controls. The effect was sustained until T12, when body weight z-score values remained 
similar among the 3 groups (Figure 2, Panel a). Slight but not significant differences were found at 
T0 for length z-score when CMA subjects (Groups 1 and 2) and healthy controls (Group 3) were 
compared. In both CMA groups, comparable increase in length was also observed. At T3, a 
difference in length z-score was observed between CMA patients and healthy children (Group 3). 
At T6, differences in length z-score were observed only in children treated with AAF, but not in 
children treated with eHWF. At T12, length z-score values were not significantly different among 
the 3 groups (Figure 2, Panel b). No differences at any time point were found for the three groups 
regarding the head circumference z-score (Figure 2, Panel c). 
The intake of energy and proteins at each study point for the three study groups are reported in 
Table 4. Study formulas were well accepted and tolerated by all CMA patients, and energy and 
protein intake levels were comparable in Groups 1 and 2. A higher protein intake was found for 
CMA subjects at 12 months compared to Group 3.  
The median values of protein metabolism biomarkers are reported in Table 5. At T0 and at T3, all 
CMA subjects showed protein metabolism biomarkers within normal range. No significant 
differences between Groups 1 and 2 were observed, with the exception of IGF-1 at T0 and urea at 
T3 median values, which were significantly higher in subjects receiving eHWF, but still within the 
normal range.  
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There was no centre effect.  
  
Discussion 
 
Although studies have demonstrated that AAF is effective for treating symptoms in virtually all 
infants with CMA, few studies have focused on the long-term efficacy of this type of formula in 
supporting adequate growth during infancy. Most studies on AAF were conducted over a relatively 
short period of observation in infants with CMA or in healthy subjects, and most studies were not 
designed to measure effects on growth (14–16, 23–25). The safety of long-term AAF use to support 
growth in CMA infants is an important issue, especially during the last decade when increased 
disease clinical severity and risk of persistence have been observed (13,23). As the persistence of 
CMA continues to increase, AAF use will likely increase, especially for infants with severe CMA 
and for specific subsets of infants (12). The present study was designed to comparatively assess the 
long-term effect on body growth of CMA infants fed an AAF versus an eHWF in a randomised 
controlled trial that met the robust proposed criteria (24). Our results show that long-term use of 
AAF is safe and able to stimulate a growth pattern similar to eHWF in CMA children. Both 
formulas, despite substantial differences in the form of protein components, were able to stimulate a 
progressive normalisation of anthropometric parameters in these patients without relevant alteration 
in protein metabolism as demonstrated by the serum biomarkers analysed in the study. These data 
are well in line with previous observations that AAF supports normal growth of healthy infants 
comparable to that of subjects fed eHWF (24). Small different body growth effects of AAF and 
eHWF have been described in two previous studies evaluating CMA infants during a 6- or 9-month 
intervention (26,27). The concomitant enrolment of patients affected by multiple food allergies, the 
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lack of detailed information on dietary intake, and the lack of concomitant evaluation of healthy 
controls make it difficult to interpret these data.  
According to our findings, we can confirm that CMA is an at-risk condition for body growth. All 
CMA paediatric patients in our study presented with a negative body weight z-score at recruitment. 
Nutritional intervention with AAF or eHWF was equally effective in normalising these parameters. 
Beginning 3 months after randomisation, the two formulas led the body weight z-score toward the 
scores of healthy controls and 0 value of normality. The trajectories of these two interventions were 
very similar for all the examined parameters. Weight-for-age and length-for-age tracking were 
similar, which indicates that equal weight-gain velocity is achievable with either of these two 
different dietary approaches in CMA paediatric patients. A strength of our study is that diet and 
formula intake were assessed systematically. Parents completed 7-day intake records at enrolment 
and at 3, 6, and 12 months. The volume of formula consumed and the energy intake were similar 
between groups throughout the study. The similarity of these effects could derive from similar 
effects on satiation signals and metabolism. Thus, as previously reported by others (28), the 
detection of small peptides or free amino acids in the infant’s gut after feeding may induce similar 
satiation signals and stimulate earlier meal termination and increased energy expenditure for infants 
who consumed these formulas.  
 
Conclusion  
We observed that after the 6
th
 month of life, and within the support of an individualised dietary 
approach, AAF and eHWF supplied for a 12-month period are associated with a progressive 
recovery of body growth and normal protein metabolism. The choice between the two dietary 
strategies in CMA children should rely mainly on clinical considerations. 
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Figure legends 
Figure 1. The flow of children through the study. 
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Figure 2. Study subject z-scores during the study period. Weight for age (Panel a), length for age 
(Panel b), head circumference for age (Panel c).  
HC = healthy controls; eHWF = extensively hydrolysed whey formula; AAF = amino acid–based 
formula. Data are expressed as median. Error bars are 95% CI.  
 
 
  
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Table 1. Nutrients composition of the study formulas 
 
  Neocate LCP Neocate Advance Hypolac Follow-on formula Growing-up  
milk 
100 ml  
(13.8% p/v) 
100 ml  
(15%p/v) 
100 ml 
(13.5%p/v) 
100 ml  
(14%p/v) 
100 ml 
(13.4%p/v) 
Energy kcal 67 60 62.5 68 65 
Proteins  g 1.8 1.5 1.6 1.4 1.6 
Carbohydrate g 7.2 8.8 6.5 8.2 8 
Sugar g 0.65 0.8 1.3 6.1 6.6 
Total fat g 3.4 2.1 3.4 3.2 3 
SFA g 1.2 0.8 - 1 1.5 
MUFA g 1.3 0.92 - 1.6 0.9 
PUFA g 0.66 0.29 - 0.6 0.6 
Linoleic acid (LA) mg 579 225 440 532 500 
Linolenic acid  (ALA) mg 57.8 60 50 49 60 
Arachidonic acid mg 11.3 - - - - 
DHA mg 11.3 - - - - 
MCT  (%  total fat) 4 35 - - - 
LCT (%  total fat) 96 65 - - - 
LA/ALA ratio  10:1 4:1 - - - 
Nucleotides g 3.22 - - - - 
Fiber g 0 0 - 0.4 0 
Na  mg 26.1 36 25 32 34 
K mg 72.5 70.2 75 90 100 
Cl mg 53.3 55.2 50 60 71 
Ca mg 65.6 30 50 65 90 
P mg 47.1 23.3 30 43 59 
Mg mg 7 7.5 5 8.1 9.5 
Fe mg 1 0.372 0.7 1.2 1.2 
Cu μg 56.6 0.04 0.04 44 45 
Zn mg 0.73 0.3 0.6 0.6 0.9 
Mn mg 0.03 0.03 0.02 0.03 9 
I μg 13.8 4.2 7.5 20 20 
Mo μg 1.6 2.1 <5 - - 
Se μg 2 1.5 1 1.6 1.6 
Cr μg 1.5 0.75 <5 - - 
Vit. A μg-RE 56 22.2 63 72 75 
Vit. D3 μg 1.2 0.49 0.94 1.2 1.6 
Vit. E μg-α-TE 0.67 0.35 1.3 1.6 2 
Vit. C mg 7.1 1.98 9.4 10 15 
Vit. K1 μg 5.9 2.1 3.8 7.4 5 
Thiamin mg 0.07 0.036 0.05 0.125 0.16 
Riboflavin mg 0.07 0.048 0.08 0.17 0.18 
Niacin mg-NE 1.4 0.57 0.63 0.602 0.495 
Pantothenic acid mg 0.4 0.15 0.31 0.7 0.6 
Vit. B6 mg 0.07 0.05 0.04 0.06 0.1 
Folate μg 8.8 6 7.5 18 15 
Vit. B12 μg 0.18 0.042 0.19 0.2 0.25 
Biotin μg 2.6 1.2 1.5 2.5 3 
Choline mg 13.2 11.52 6.3 - - 
Inositol mg 14. 9 1.13 4 13 - 
Osmolarity mOsm/l 310 520 175 - - 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
Table 2. Main features of the study population at enrolment 
AAF = amino acid–based formula; eHWF = extensively hydrolysed whey formula.  
*Data are reported as median and (IQR) 
 
  
 
Subjects with 
CMA treated 
with AAF 
n=25 
Subjects with 
CMA treated  
with eHWF 
n=25 
Healthy 
controls 
 
n=25 
Male, n (%)  15 (60) 14 (56) 12 (48) 
Age, months (±SD)  6.5 (1.4) 6.8 (1.6) 5.5 (0.5) 
Duration of breastfeeding, months (±SD)  4.4 (1.4) 4.9 (1.7) 4.8 (1.1) 
Age of weaning, months (±SD)  5 (0.9) 5.3 (0.6) 5.1 (0.7) 
Energy intake, Kcal/kg/day*   98.2 (5.9) 96.8 (6.4) 101.3 (15.1) 
Protein intake, gr/kg/day* 2.2 (0.4) 2.2 (0.3) 2.3 (0.3)  
Suspected IgE mediated mechanism, n (%)  13 (52) 15 (60) --- 
Gastrointestinal symptoms, n (%)  12 (48) 16 (64) --- 
Cutaneous symptoms, n (%)  13 (52) 16 (64) --- 
Respiratory symptoms, n (%)  4 (16) 4 (16) --- 
Urea, mmol/L* 3.5 (1.9) 3.8 (1.8) --- 
Total protein, g/L* 65.6 (7.3) 65 (10.6) --- 
Albumin, g/dl* 4 (0.6) 4.1 (0.4) --- 
Retinol binding protein, mg/L* 22.3 (28.7) 30.5 (30) --- 
Insulin-like growth factor 1, μg/L* 52 (30) 64 (65)  --- 
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Table 3. Main features of subjects with positive diagnostic double-blind placebo-controlled food 
challenge 
 
Subjects with 
CMA treated 
with AAF 
n=21 
Subjects with 
CMA treated  
with eHWF 
n=19 
Healthy 
controls 
 
n=25 
Male, n (%)  13 (61.9) 11 (57.9) 12 (48) 
Age, months (±SD)  6.5 (1.5) 7 (1.7) 5.5 (0.5) 
Duration of breastfeeding, months (±SD)  4.3 (1.6) 5 (2) 4.8 (1.1) 
Age of weaning, months (±SD)  4.9 (0.9) 5.3 (0.6) 5.1 (0.7) 
IgE mediated mechanism, n (%)  10 (47.6) 14 (73.7) --- 
Gastrointestinal symptoms, n (%)  11 (52.4) 11 (57.9) --- 
Cutaneous symptoms, n (%)  10 (47.6) 12 (63.2) --- 
Respiratory symptoms, n (%)  4 (19) 4 (21.1) --- 
 AAF = amino acid–based formula; eHWF = extensively hydrolysed whey formula.  
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Table 4. Energy and protein intake in study subjects during the study period  
 
 
Months  
Subjects with 
CMA treated  
with AAF 
n=21 
Subjects with 
CMA treated  
with eHWF 
n=19 
Healthy 
controls 
n=25 
Energy intake, Kcal/kg/day     
  
 0  98.4 (8.8) 96.0 (7.8) 101.3 (15.1) 
 3  102.9 (7.8) 96.9 (12.5) 98.2 (9) 
 6  94.8 (6.9) 95.2 (12.5) 99.5 (9.2) 
 12  89.7 (5.8) 90.6 (8.8) 96.4 (8.7) 
Protein intake, gr/kg/day      
 0  2.1 (0.3) 2.3 (0.3) 2.3 (0.3) 
 3  2.2 (0.4) 2.3 (0.4) 2.1 (0.4) 
 6  2.2 (0.2) 2.2 (0.1) 2.1 (0.3) 
 12   2.3 (0.1)
a
  2.3 (0.1)
a
  2.1 (0.3)
b
 
Data are reported as median and (IQR) 
Different superscript indicate a significant difference (p=0.04 and p=0.015, respectively)  
AAF = amino acid–based formula; eHWF = extensively hydrolysed whey formula. 
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Table 5. Biomarkers of protein metabolism 
 
  
Months  
Subjects with CMA 
treated with AAF 
n=21 
Subjects with CMA 
treated with eHWF 
n=19 
Urea, mmol/L  0 3.1 (1.68) 3.8 (2.1) 
 3 3.7 (1.9)
a
 4.3 (2)
b
 
    
Total protein, g/L  0 64.1 (6.6) 63 (10) 
 3 64.9 (10.7) 65.6 (7.5) 
    
Albumin, g/dl  0 3.9 (0.6) 4.1 (0.4) 
 3 4.3 (0.7) 4 (0.6) 
    
Retinol binding protein, mg/L  0 16.6 (23.5) 26.6 (9.7) 
 3 27.9 (14.3) 27.2 (11.4) 
    
Insulin-like growth factor 1, μg/L  0 56 (30.5)
a
 77 (58)
b
 
 3 65.5 (52.2) 71 (66) 
Data are reported as median and (IQR) 
Different superscript indicate a significant difference (p=0.033 and p=0.016, respectively)  
AAF = amino acid–based formula; eHWF = extensively hydrolysed whey formula. 
 
 
 
